RIGL
RIGL
US7665597024
Rigel Pharmaceuticals, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 85/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±85.6% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.

Beta (Market Relation)
1.19x
Above average
Volatility (5Y p.a.)
85.6% p.a.
5-Year Horizon
Max Drawdown (5Y)
-81.2%
5-Year Horizon
Sharpe Ratio
0.06
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +69.4%
3 Years 73.4% -50.8% 0.92 +70.1%
5 Years 85.6% -81.2% 0.06 +7.2%
10 Years 81.1% -86.4% -0.01 +2.1%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (85.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.4% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
11.35
ende